GEOFFREY NICHOL
CIK 1214505 · Executive Vice President, R&D · last filed 2026-01-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
4
Total Filings
25
Lifetime Open-Market Net
$0
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TPST | Director | — | $0.87 | — | $0 | 6 | 2026-01-28 |
| Tempest Therapeutics, Inc. (MLND) Delisted | Director | — | $15.90 | — | $0 | 2 | 2020-06-23 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Executive Vice President, R&D | 159,676 | $0.18 | $28.4K | $0 | 7 | 2015-12-15 |
| MEDX | Senior Vice President | 0 | $36.03 | $0 | $0 | 9 | 2009-09-01 |
Recent Filings · Page 2 of 3
25 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-12-15 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | −4,243 | -$615.2K | EDGAR |
| 2013-12-13 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | +12,389 | -$274.0K | EDGAR |
| 2012-12-10 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Grant (A) | +55,000 | $0 | EDGAR |
| 2011-12-12 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Grant (A) | +75,000 | $0 | EDGAR |
| 2011-07-11 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-09-03 | — | Disp (D) | — | $0 | |
| 2009-09-01 | MEDX | U | −15,926 | -$254.8K | EDGAR |
| 2009-08-31 | MEDX | U | −35,926 | -$574.8K | EDGAR |
| 2009-03-17 | MEDX | Grant (A) | — | $0 | EDGAR |
| 2009-03-06 | MEDX | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.